Related references
Note: Only part of the references are listed.Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response
Daniel E. Lowther et al.
ACTA NEUROPATHOLOGICA (2013)
Emerging role of interleukin-22 in autoimmune diseases
Hai-Feng Pan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Promotion and prevention of autoimmune disease by CD8+T cells
David M. Gravano et al.
JOURNAL OF AUTOIMMUNITY (2013)
Immunomodulatory Effects of Interferons in Malignancies
Joseph Bekisz et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2013)
Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation
Hui Huang et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study
Suhayl Dhib-Jalbut et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models
Xu Wang et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2013)
Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?
A. H. Nuyts et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39
Ivan D. Mascanfroni et al.
NATURE IMMUNOLOGY (2013)
Interleukin-17 and a tale of two autoimmune diseases
Dominique L. P. Baeten et al.
NATURE MEDICINE (2013)
Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells
Katja Derkow et al.
PLOS ONE (2013)
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
Tamara Castillo-Trivino et al.
PLOS ONE (2013)
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis
E. Croze et al.
PHARMACOGENOMICS JOURNAL (2013)
Genomic responses in mouse models poorly mimic human inflammatory diseases
Junhee Seok et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Pathogen sensors and chemokine receptors in dendritic cell subsets
Tsuneyasu Kaisho
VACCINE (2012)
Gut, Bugs, and Brain: Role of Commensal Bacteria in the Control of Central Nervous System Disease
Javier Ochoa-Reparaz et al.
ANNALS OF NEUROLOGY (2011)
Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin
Igal Ifergan et al.
BRAIN (2011)
Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: An ongoing story
Ana Caminero et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Kerstin Berer et al.
NATURE (2011)
Viruses and Multiple Sclerosis
Gregory P. Owens et al.
NEUROSCIENTIST (2011)
Intracerebral Human Regulatory T Cells: Analysis of CD4+CD25+FOXP3+ T Cells in Brain Lesions and Cerebrospinal Fluid of Multiple Sclerosis Patients
Benedikt Fritzsching et al.
PLOS ONE (2011)
Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple Sclerosis
Richard A. Rudick et al.
PLOS ONE (2011)
Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis
Yun Kyung Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Interferon-β Inhibits Toll-Like Receptor 9 Processing in Multiple Sclerosis
Konstantin E. Balashov et al.
ANNALS OF NEUROLOGY (2010)
IL-22RA2 Associates with Multiple Sclerosis and Macrophage Effector Mechanisms in Experimental Neuroinflammation
Amennai D. Beyeen et al.
JOURNAL OF IMMUNOLOGY (2010)
Interferon-β mechanisms of action in multiple sclerosis
Suhayl Dhib-Jalbut et al.
NEUROLOGY (2010)
Multiple sclerosis immunology The healthy immune system vs the MS immune system
Lloyd H. Kasper et al.
NEUROLOGY (2010)
Atacicept: targeting B cells in multiple sclerosis
Hans-Peter Hartung et al.
Therapeutic Advances in Neurological Disorders (2010)
T-Helper 17 Cells Expand in Multiple Sclerosis and Are Inhibited by Interferon-β
Luca Durelli et al.
ANNALS OF NEUROLOGY (2009)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis
A. Bayas et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis
Manuel Comabella et al.
CLINICAL IMMUNOLOGY (2009)
Interferon-β increases BAFF levels in multiple sclerosis:: implications for B cell autoimmunity
M. Krumbholz et al.
BRAIN (2008)
The type IIFN induction pathway constrains Th17-mediated autoimmune inflammation in mice
Beichu Guo et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Immune cell entry into the central nervous system: Involvement of adhesion molecules and chemokines
Britta Engelhardt
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Repeated subcutaneous injections of IL12/23 P40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
Benjamin M. Segal et al.
LANCET NEUROLOGY (2008)
B cells as therapeutic targets in autoimmune neurological disorders
Marinos C. Dalakas
NATURE CLINICAL PRACTICE NEUROLOGY (2008)
CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta
Anna-Maija Vallittu et al.
NEUROLOGICAL RESEARCH (2007)
Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response
Jerome J. Graber et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis
M Stasiolek et al.
BRAIN (2006)
Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta
C Boz et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2006)
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation
E Meinl et al.
ANNALS OF NEUROLOGY (2006)
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma
M Krumbholz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS
E Waubant et al.
NEUROLOGY (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
S Dhib-Jalbut
NEUROLOGY (2002)
Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: Implications for Th1-mediated diseases
X Feng et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2002)
BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells?
C Stadelmann et al.
BRAIN (2002)